EPISODE · Oct 3, 2024 · 36 MIN
EASL Studio Podcast: Why does WHO engagement with Steatotic Liver Disease matter?
from EASL Podcasts · host European Association for the Study of the Liver
This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition.FacultyJeffrey Lazarus (Moderator)Mazen Noureddin (Faculty)Shira Zelber-Sagi (Faculty)Kremlin Wickramasinghe (Faculty)The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk.Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode.Related episodesEASL Studio at the Congress 2024: MASLD anno 2024: A rapidly changing landscapeEASL Studio S6E7: The impact of policy measure in preventing liver diseases: The Hepahealth II studyEASL Studio S6E1: Do we solve MASLD by treating obesity?EASL Studio S5E2: Are 30% of the global population sick? A critical view on Steatotic Liver Disease and care pathwaysEASL Studio S4 Special Edition 2: Promoting Liver Health: An urgent call for action at WHOEASL Studio S4E8: The central role of alcohol and food policies on liver healthAll EASL Studio Podcasts are available on EASL Campus.
Embed this episode
What this episode covers
This episode is organised in collaboration with the Healthy Livers, Healthy Lives Coalition. Faculty Jeffrey Lazarus (Moderator)Mazen Noureddin (Faculty)Shira Zelber-Sagi (Faculty)Kremlin Wickramasinghe (Faculty)The Healthy Livers, Healthy Lives Coalition’s activities are supported by Boehringer Ingelheim, Echosens, MSD, and Novo Nordisk. Our industry partners have had no input into the content of the Health Livers, Healthy Lives Coalition’s activities or this EASL Studio episode. Related epi...
NOW PLAYING
EASL Studio Podcast: Why does WHO engagement with Steatotic Liver Disease matter?
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.